GENMAB A/S -SP ADR (GMAB) Fundamental Analysis & Valuation

NASDAQ:GMAB • US3723032062

27.72 USD
+0.48 (+1.76%)
Last: Mar 10, 2026, 09:57 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This GMAB fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

6

Overall GMAB gets a fundamental rating of 6 out of 10. We evaluated GMAB against 519 industry peers in the Biotechnology industry. While GMAB has a great profitability rating, there are some minor concerns on its financial health. GMAB has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

7

1. GMAB Profitability Analysis

1.1 Basic Checks

  • In the past year GMAB was profitable.
  • In the past year GMAB had a positive cash flow from operations.
  • Each year in the past 5 years GMAB has been profitable.
  • Each year in the past 5 years GMAB had a positive operating cash flow.
GMAB Yearly Net Income VS EBIT VS OCF VS FCFGMAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

1.2 Ratios

  • With an excellent Return On Assets value of 7.48%, GMAB belongs to the best of the industry, outperforming 92.49% of the companies in the same industry.
  • With an excellent Return On Equity value of 16.47%, GMAB belongs to the best of the industry, outperforming 94.80% of the companies in the same industry.
  • Looking at the Return On Invested Capital, with a value of 9.04%, GMAB belongs to the top of the industry, outperforming 93.45% of the companies in the same industry.
  • GMAB had an Average Return On Invested Capital over the past 3 years of 12.48%. This is significantly below the industry average of 19.44%.
Industry RankSector Rank
ROA 7.48%
ROE 16.47%
ROIC 9.04%
ROA(3y)12.49%
ROA(5y)13.54%
ROE(3y)17.43%
ROE(5y)17.15%
ROIC(3y)12.48%
ROIC(5y)13.32%
GMAB Yearly ROA, ROE, ROICGMAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15 20 25

1.3 Margins

  • GMAB's Profit Margin of 25.89% is amongst the best of the industry. GMAB outperforms 94.80% of its industry peers.
  • GMAB's Profit Margin has declined in the last couple of years.
  • Looking at the Operating Margin, with a value of 33.60%, GMAB belongs to the top of the industry, outperforming 96.53% of the companies in the same industry.
  • GMAB's Operating Margin has declined in the last couple of years.
  • GMAB has a better Gross Margin (93.60%) than 94.41% of its industry peers.
  • In the last couple of years the Gross Margin of GMAB has declined.
Industry RankSector Rank
OM 33.6%
PM (TTM) 25.89%
GM 93.6%
OM growth 3Y-7.78%
OM growth 5Y-11.4%
PM growth 3Y-11.69%
PM growth 5Y-11.27%
GM growth 3Y-2.18%
GM growth 5YN/A
GMAB Yearly Profit, Operating, Gross MarginsGMAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. GMAB Health Analysis

2.1 Basic Checks

  • GMAB has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • Compared to 1 year ago, GMAB has less shares outstanding
  • The number of shares outstanding for GMAB has been reduced compared to 5 years ago.
  • Compared to 1 year ago, GMAB has a worse debt to assets ratio.
GMAB Yearly Shares OutstandingGMAB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M
GMAB Yearly Total Debt VS Total AssetsGMAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B 10B

2.2 Solvency

  • An Altman-Z score of 2.62 indicates that GMAB is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • The Altman-Z score of GMAB (2.62) is better than 66.28% of its industry peers.
  • GMAB has a debt to FCF ratio of 4.80. This is a neutral value as GMAB would need 4.80 years to pay back of all of its debts.
  • The Debt to FCF ratio of GMAB (4.80) is better than 92.10% of its industry peers.
  • A Debt/Equity ratio of 0.88 indicates that GMAB is somewhat dependend on debt financing.
  • GMAB has a Debt to Equity ratio of 0.88. This is in the lower half of the industry: GMAB underperforms 73.41% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.88
Debt/FCF 4.8
Altman-Z 2.62
ROIC/WACC1.42
WACC6.36%
GMAB Yearly LT Debt VS Equity VS FCFGMAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B 5B

2.3 Liquidity

  • GMAB has a Current Ratio of 2.02. This indicates that GMAB is financially healthy and has no problem in meeting its short term obligations.
  • With a Current ratio value of 2.02, GMAB is not doing good in the industry: 76.69% of the companies in the same industry are doing better.
  • A Quick Ratio of 2.01 indicates that GMAB has no problem at all paying its short term obligations.
  • With a Quick ratio value of 2.01, GMAB is not doing good in the industry: 74.95% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.02
Quick Ratio 2.01
GMAB Yearly Current Assets VS Current LiabilitesGMAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. GMAB Growth Analysis

3.1 Past

  • The earnings per share for GMAB have decreased by -2.61% in the last year.
  • Measured over the past years, GMAB shows a quite strong growth in Earnings Per Share. The EPS has been growing by 9.47% on average per year.
  • Looking at the last year, GMAB shows a quite strong growth in Revenue. The Revenue has grown by 19.25% in the last year.
  • GMAB shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 19.19% yearly.
EPS 1Y (TTM)-2.61%
EPS 3Y13.49%
EPS 5Y9.47%
EPS Q2Q%-75.02%
Revenue 1Y (TTM)19.25%
Revenue growth 3Y21.97%
Revenue growth 5Y19.19%
Sales Q2Q%14.88%

3.2 Future

  • The Earnings Per Share is expected to grow by 9.88% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 12.86% on average over the next years. This is quite good.
EPS Next Y-15.07%
EPS Next 2Y5.16%
EPS Next 3Y17.95%
EPS Next 5Y9.88%
Revenue Next Year18.34%
Revenue Next 2Y16.58%
Revenue Next 3Y17.06%
Revenue Next 5Y12.86%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
GMAB Yearly Revenue VS EstimatesGMAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B
GMAB Yearly EPS VS EstimatesGMAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

6

4. GMAB Valuation Analysis

4.1 Price/Earnings Ratio

  • GMAB is valuated correctly with a Price/Earnings ratio of 15.84.
  • GMAB's Price/Earnings ratio is rather cheap when compared to the industry. GMAB is cheaper than 95.18% of the companies in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 26.45, GMAB is valued a bit cheaper.
  • With a Price/Forward Earnings ratio of 18.67, GMAB is valued on the expensive side.
  • 94.61% of the companies in the same industry are more expensive than GMAB, based on the Price/Forward Earnings ratio.
  • GMAB is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 24.65, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 15.84
Fwd PE 18.67
GMAB Price Earnings VS Forward Price EarningsGMAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • 94.61% of the companies in the same industry are more expensive than GMAB, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, GMAB is valued cheaper than 96.72% of the companies in the same industry.
Industry RankSector Rank
P/FCF 15.1
EV/EBITDA 15.51
GMAB Per share dataGMAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5

4.3 Compensation for Growth

  • The decent profitability rating of GMAB may justify a higher PE ratio.
  • A more expensive valuation may be justified as GMAB's earnings are expected to grow with 17.95% in the coming years.
PEG (NY)N/A
PEG (5Y)1.67
EPS Next 2Y5.16%
EPS Next 3Y17.95%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. GMAB Dividend Analysis

5.1 Amount

  • No dividends for GMAB!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

GMAB Fundamentals: All Metrics, Ratios and Statistics

GENMAB A/S -SP ADR

NASDAQ:GMAB (3/10/2026, 9:57:01 AM)

27.72

+0.48 (+1.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-18
Earnings (Next)05-07
Inst Owners42.45%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap17.08B
Revenue(TTM)3.72B
Net Income(TTM)963.00M
Analysts73.85
Price Target95.18 (243.36%)
Short Float %1.34%
Short Ratio4.48
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.37%
Min EPS beat(2)-39.11%
Max EPS beat(2)36.36%
EPS beat(4)3
Avg EPS beat(4)18.01%
Min EPS beat(4)-39.11%
Max EPS beat(4)49.64%
EPS beat(8)6
Avg EPS beat(8)33.48%
EPS beat(12)8
Avg EPS beat(12)19.29%
EPS beat(16)11
Avg EPS beat(16)25.94%
Revenue beat(2)2
Avg Revenue beat(2)0.64%
Min Revenue beat(2)0.19%
Max Revenue beat(2)1.09%
Revenue beat(4)2
Avg Revenue beat(4)-1.97%
Min Revenue beat(4)-7.66%
Max Revenue beat(4)1.09%
Revenue beat(8)6
Avg Revenue beat(8)225.98%
Revenue beat(12)10
Avg Revenue beat(12)350.6%
Revenue beat(16)14
Avg Revenue beat(16)264.87%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-33.1%
EPS NQ rev (3m)-33.1%
EPS NY rev (1m)-12.79%
EPS NY rev (3m)-18.6%
Revenue NQ rev (1m)0.88%
Revenue NQ rev (3m)0.88%
Revenue NY rev (1m)0.81%
Revenue NY rev (3m)0.67%
Valuation
Industry RankSector Rank
PE 15.84
Fwd PE 18.67
P/S 4.59
P/FCF 15.1
P/OCF 14.4
P/B 2.92
P/tB N/A
EV/EBITDA 15.51
EPS(TTM)1.75
EY6.31%
EPS(NY)1.48
Fwd EY5.36%
FCF(TTM)1.84
FCFY6.62%
OCF(TTM)1.93
OCFY6.95%
SpS6.04
BVpS9.49
TBVpS-5.89
PEG (NY)N/A
PEG (5Y)1.67
Graham Number19.33
Profitability
Industry RankSector Rank
ROA 7.48%
ROE 16.47%
ROCE 10.92%
ROIC 9.04%
ROICexc 10.63%
ROICexgc 409.04%
OM 33.6%
PM (TTM) 25.89%
GM 93.6%
FCFM 30.4%
ROA(3y)12.49%
ROA(5y)13.54%
ROE(3y)17.43%
ROE(5y)17.15%
ROIC(3y)12.48%
ROIC(5y)13.32%
ROICexc(3y)44.94%
ROICexc(5y)57.79%
ROICexgc(3y)214.92%
ROICexgc(5y)161.21%
ROCE(3y)15.08%
ROCE(5y)16.09%
ROICexgc growth 3Y67.71%
ROICexgc growth 5Y24.23%
ROICexc growth 3Y-49.91%
ROICexc growth 5Y-39%
OM growth 3Y-7.78%
OM growth 5Y-11.4%
PM growth 3Y-11.69%
PM growth 5Y-11.27%
GM growth 3Y-2.18%
GM growth 5YN/A
F-Score4
Asset Turnover0.29
Health
Industry RankSector Rank
Debt/Equity 0.88
Debt/FCF 4.8
Debt/EBITDA 3.89
Cap/Depr 77.46%
Cap/Sales 1.48%
Interest Coverage 125
Cash Conversion 89.78%
Profit Quality 117.45%
Current Ratio 2.02
Quick Ratio 2.01
Altman-Z 2.62
F-Score4
WACC6.36%
ROIC/WACC1.42
Cap/Depr(3y)92.84%
Cap/Depr(5y)93.54%
Cap/Sales(3y)1.72%
Cap/Sales(5y)2.07%
Profit Quality(3y)124.53%
Profit Quality(5y)101.27%
High Growth Momentum
Growth
EPS 1Y (TTM)-2.61%
EPS 3Y13.49%
EPS 5Y9.47%
EPS Q2Q%-75.02%
EPS Next Y-15.07%
EPS Next 2Y5.16%
EPS Next 3Y17.95%
EPS Next 5Y9.88%
Revenue 1Y (TTM)19.25%
Revenue growth 3Y21.97%
Revenue growth 5Y19.19%
Sales Q2Q%14.88%
Revenue Next Year18.34%
Revenue Next 2Y16.58%
Revenue Next 3Y17.06%
Revenue Next 5Y12.86%
EBIT growth 1Y24.57%
EBIT growth 3Y12.48%
EBIT growth 5Y5.6%
EBIT Next Year-1.37%
EBIT Next 3Y19.49%
EBIT Next 5Y4.76%
FCF growth 1Y4.43%
FCF growth 3Y30.57%
FCF growth 5Y3.84%
OCF growth 1Y5.23%
OCF growth 3Y28.97%
OCF growth 5Y3.81%

GENMAB A/S -SP ADR / GMAB FAQ

What is the ChartMill fundamental rating of GENMAB A/S -SP ADR (GMAB) stock?

ChartMill assigns a fundamental rating of 6 / 10 to GMAB.


What is the valuation status for GMAB stock?

ChartMill assigns a valuation rating of 6 / 10 to GENMAB A/S -SP ADR (GMAB). This can be considered as Fairly Valued.


Can you provide the profitability details for GENMAB A/S -SP ADR?

GENMAB A/S -SP ADR (GMAB) has a profitability rating of 7 / 10.


Can you provide the PE and PB ratios for GMAB stock?

The Price/Earnings (PE) ratio for GENMAB A/S -SP ADR (GMAB) is 15.84 and the Price/Book (PB) ratio is 2.92.


Can you provide the financial health for GMAB stock?

The financial health rating of GENMAB A/S -SP ADR (GMAB) is 6 / 10.